Agios Pharmaceuticals (AGIO) – Investment Analysts’ Weekly Ratings Changes

Agios Pharmaceuticals (NASDAQ: AGIO) recently received a number of ratings updates from brokerages and research firms:

• 11/9/2024 – Agios Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/1/2024 – Agios Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/1/2024 – Agios Pharmaceuticals had its price target raised by analysts at Scotiabank from $51.00 to $53.00. They now have a “sector outperform” rating on the stock.
• 11/1/2024 – Agios Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
• 10/16/2024 – Agios Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $51.00 price target on the stock.
• 10/16/2024 – Agios Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/10/2024 – Agios Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
• 9/27/2024 – Agios Pharmaceuticals was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $56.00 price target on the stock, down previously from $60.00.
• 9/27/2024 – Agios Pharmaceuticals was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/20/2024 – Agios Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO traded up $1.52 during midday trading on Tuesday, reaching $54.41. 496,895 shares of the company’s stock were exchanged, compared to its average volume of 702,731. The company’s 50 day simple moving average is $46.62 and its two-hundred day simple moving average is $44.07. Agios Pharmaceuticals, Inc. has a 12 month low of $20.96 and a 12 month high of $62.58. The firm has a market capitalization of $3.10 billion, a PE ratio of 4.79 and a beta of 0.75.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently bought and sold shares of AGIO. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter valued at $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC boosted its position in Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals in the third quarter valued at about $146,000.

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.